CoChat
Sign Up
Cited by 258Pharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsBariatric Surgery and Outcomes

Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity

Open access
Seifarth, C., Schehler, B., Schneider, H.·2012·Experimental and Clinical Endocrinology & Diabetes
DOI 10.1055/s-0032-1327734
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results. Moreover, the effectiveness in a real-life outpatient setting has not been tested until today. In this study we aimed to examine the effectiveness of metformin as a weight reducing drug in obese and overweight patients with regard to their degree of insulin resistance. DESIGN AND PATIENTS: We treated 154 consecutive patients with a body mass index ≥27 kg/m(2) in an outpatient setting over 6 months with metformin up to a dosage of 2,500 mg per day. Additionally, we included 45 untreated patients as controls. Patients were monitored for weight changes over 6 months. Before metformin treatment was started insulin sensitivity was determined in all patients by calculating HOMA index and Matsuda index after a 75 g oral glucose tolerance test. RESULTS: The mean weight loss in the metformin treated group was 5.8±7.0 kg (5.6±6.5%). Untreated controls gained 0.8±3.5 kg (0.8±3.7%) on average. Patients with severe insulin resistance lost significantly more weight as compared to insulin sensitive patients. The percentage of weight loss was independent of age, sex or BMI. CONCLUSION: Metformin is an effective drug to reduce weight in a naturalistic outpatient setting in insulin sensitive and insulin resistant overweight and obese patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-0032-1327734

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metformin supports weight loss by reducing food consumption.

    “Furthermore, it supports weight loss344 by reducing food consumption.345”

    From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [344]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 43 · Cited by 258

Research works printed but not linked: 41

  1. Meneghini L F , Orozco-Beltran D , Khunti K et al. Weight benefi cial treatments for type 2 diabetes . J Clin Endocrinol Metab 2011 ; 96 : 3337 -3353
  2. Bennett W L , Odelola O A , Wilson L M et al. Evaluation of guideline rec- ommendations on oral medications for type 2 diabetes mellitus: a systematic review . Ann Intern Med 2012 ; 156 : 27 -36
  3. Sterne J . Pharmacology and mode of action of hypoglycaemic guani- dine derivatives . In: Campbell G D . (ed.). Oral hypoglycaemic agents . London : Academic , 1969 ; 193 -245
  4. Dunaif A . Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis . Endocr Rev 1997 ; 18 : 774 -800
  5. Unlühizarci K , Keleştimur F , Bayram F et al. The eff ects of metformin on insulin resistance and ovarian steroidogenesis in women with poly- cystic ovary syndrome . Clin Endocrinol 1999 ; 51 : 231 -236
  6. Stumvoll M , Nurjhan N , Perriello G et al. Metabolic eff ects of met- formin in non-insulin-dependent diabetes mellitus . N Engl J Med 1995 ; 333 : 550 -554
  7. Lustig R H . Hypothalamic obesity: the sixth cranial endocrinopathy . The Endocrinologist 2002 ; 12 : 210 -217
  8. Sigal R J , El-Hashimy M , Martin B C et al. Acute post-challenge hyperin- sulinemia predicts weight gain . Diabetes 1997 ; 46 : 1025 -1029
  9. Odeleye O E , de Courten M , Pettitt D J et al. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children . Diabetes 1997 ; 46 : 1341 -1345
  10. Bailey D J , Turner R C . Metformin . N Engl J Med 1996 ; 334 : 574 -579
  11. Hermann L S , Melander A . Biguanides: basic aspects and clinical uses . In: Alberti KGM M , DeFronzo R A , Keen H , Zimmet P (eds.). Interna- tional textbook of diabetes mellitus . Vol. 1 : Chichester, England : John Wiley , 1992 ; 773 -795
  12. Gambineri A , Patton L , Vaccina A et al. Treatment with fl utamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome . J Clin Endocrinol Metab 2006 ; 91 : 3970 -3980
  13. Derosa G , Maffi oli P . Anti-obesity drugs: a review about their eff ects and their safety . Expert Opin Drug Saf 2012 ; 11 : 459 -471
  14. Ara R , Blake L , Gray L et al. What is the clinical eff ectiveness and cost-eff ectiveness of using drugs in treating obese patients in primary care? A systematic review . Health Technol Assess 2012 ; 1 : 1 -195
  15. Bray G A , Ryan D H . Medical Therapy for the Patient with Obesity . Cir- culation 2012 ; 125 : 1695 -1703
  16. Setter S M , Iltz J L , Thams J et al. Metformin hydrochloride in the treat- ment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy . Clin Ther 2003 ; 25 : 2991 -3026
  17. Haff ner S , Temprosa M , Crandall J et al. Intensive lifestyle intervention or metformin on infl ammation and coagulation in participants with impaired glucose tolerance . Diabetes 2005 ; 54 : 1566 -1572
  18. Wang M , Tong J H , Zhu G et al. Metformin for treatment of antipsy- chotic-induced weight gain: A randomized, placebo-controlled study . Schizophr Res 2012 ; 138 : 54 -57
  19. Bushe C J , Bradley A J , Doshi S et al. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies . Int J Clin Pract 2009 ; 63 : 1743 -1761
  20. Park M H , Kinra S , Ward K J et al. Metformin for obesity in children and adolescents: a systematic review . Diabetes Care 2009 ; 32 : 1743 -1745 28
  21. Mauras N , DelGiorno C , Hossain J et al. Metformin use in children with obesity and normal glucose tolerance-eff ects on cardiovascular mark- ers and intrahepatic fat . J Pediatr Endocrinol Metab 2012 ; 25 : 33 -40 29
  22. Metwally M , Amer S , Li T C et al. of metformin versus orlistat for the management of obese anovulatory women . Hum Reprod 2009 ; 24 : 966 -975
  23. Harborne L R , Sattar N , Norman J E et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses . J Clin Endocrinol Metab 2005 ; 90 : 4593 -4598
  24. Ghandi S , Afl atoonian A , Tabibnejad N et al. The eff ects of metformin or orlistat on obese women with polycystic ovary syndrome: a pro- spective randomized open-label study . J Assist Reprod Genet 2011 ; 28 : 591 -596
  25. Matsuda M , DeFronzo R A . Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp . Diabetes Care 1999 ; 22 : 1462 -1470
  26. Levri K M , Slaymaker E , Last A et al. Metformin as treatment for over- weight and obese adults: a systematic review . Ann Fam Med 2005 ; 3 : 457 -461
  27. Goodpaster B H , Kelley D E , Wing R R et al. Eff ects of weight loss on regional fat distribution and insulin sensitivity in obesity . Diabetes 1999 ; 48 : 839 -847
  28. Gokcel A , Gumurdulu Y , Karakose H et al. Evaluation of the safety and effi cacy of sibutramine, orlistat and metformin in the treatment of obesity . Diabetes Obes Metab 2002 ; 4 : 49 -55
  29. Mogul H R , Peterson S J , Weinstein B I et al. Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modifi ed diet in eugly- cemic, hyperinsulinemic, midlife women (Syndrome W) . Heart Dis 2003 ; 5 : 384 -392
  30. Dohm G L , Tapscott E , Pories W et al. An in vitro human muscle prepa- ration suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic sub- jects . J Clin Invest 1988 ; 82 : 486 -494
  31. Oppert J M , Nadeau A , Tremblay A et al. Plasma glucose, insulin, and glucagon before and after long-term overfeeding in identical twins . Metabolism 1995 ; 44 : 96 -105
  32. Luyckx A S , Lefevbre P J . Plasma insulin in reactive hypoglycemia . Dia- betes 1971 ; 20 : 435 -442
  33. Schultes B , Oltmanns K M , Kern W et al. Modulation of hunger by plasma glucose and metformin . J Clin Endocrinol Metab 2003 ; 88 : 1133 -1141
  34. Giannarelli R , Aragona M , Coppelli A et al. Reducing insulin resistance with metformin: the evidence today . Diabetes Metab 2003 ; 29 : 28 -35
  35. Mizuno T M , Funabashi T , Kleopoulos S P et al. Specifi c preservation of biosynthetic responses to insulin in adipose tissue may contribute to hyperleptinemia in insulin-resistant obese mice . J Nutr 2004 ; 134 : 1045 -1050
  36. Cusin I , Terrettaz J , Rohner-Jeanrenaud F et al. Hyperinsulinemia increases the amount of GLUT4 mRNA in white adipose tissue and decreases that of muscles: a clue for increased fat depot and insulin resistance . Endocrinology 1990 ; 127 : 3246 -3248
  37. Tan S , Hahn S , Benson S et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance . Eur J Endocrinol 2007 ; 157 : 669 -676
  38. Paolisso G , Amato L , Eccellente R et al. Eff ect of metformin on food intake in obese subjects . Eur J Clin Invest 1998 ; 28 : 441 -446
  39. Mick G J , Wang X , Ling Fu C et al. Inhibition of leptin secretion by insulin and metformin in cultured rat adipose tissue . Biochim Biophys Acta 2000 ; 1502 : 426 -432
  40. Morin-Papunen L C , Koivunen R M , Tomas C et al. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome . J Clin Endocrinol Metab 1998 ; 83 : 2566 -2568
  41. Mannucci E , Tesi F , Bardini G et al. Eff ects of metformin on glucagon- like peptide-1 levels in obese patients with and without Type 2 dia- betes . Diabetes Nutr Metab 2004 ; 17 : 336 -342

Authors
Seifarth, C., Schehler, B., & Schneider, H.
Affiliations
  • Practice for Endocrinology, Regensburg, Germany
  • Ludwig-Maximilians-Universität München (DE)
Venue
Experimental and Clinical Endocrinology & Diabetes
Publisher
Georg Thieme Verlag KG
Published
2012-11-12
Volume
121
Issue
01
Pages
27-31
ISSN
  • 0947-7349 (ISSN-L)
  • 1439-3646
DOI
10.1055/s-0032-1327734
OpenAlex
W2047377453
Cited by
258
References
43
Citations by year
2026: 8 · 2025: 16 · 2024: 25 · 2023: 27 · 2022: 27 · 2021: 38 · 2020: 24 · 2019: 23 · 2018: 19 · 2017: 18 · 2016: 10 · 2015: 4 · 2014: 11 · 2013: 8
FWCI
5.41
Type
journal article
Language
en
Open access
Locations
  • Experimental and Clinical Endocrinology & Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
metformin, obesity, weight loss, insulin resistance, overweight, HOMA index, Matsuda index, outpatient care, non-diabetic patients
MeSH terms
Adult, Age Factors, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Obesity, Outpatients, Sex Factors, Time Factors, Weight Loss, Body Mass Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review